Free Trial

OnKure Therapeutics Q2 2024 Earnings Report

OnKure Therapeutics logo
$4.45 -0.24 (-5.12%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OnKure Therapeutics EPS Results

Actual EPS
-$1.60
Consensus EPS
-$1.70
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

OnKure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OnKure Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

OnKure Therapeutics Earnings Headlines

Equities Analysts Set Expectations for OKUR Q1 Earnings
Trump’s Treasure Map [Pic inside]
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More OnKure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email.

About OnKure Therapeutics

OnKure Therapeutics (NASDAQ:OKUR), Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

View OnKure Therapeutics Profile

More Earnings Resources from MarketBeat